Chardan Capital Initiates Lion Biotechnologies With Buy

Loading...
Loading...
Analysts at Chardan Capital initiated coverage on
Lion Biotechnologies IncLBIO
with a Buy rating. The target price for Lion Biotechnologies is set to $30. Lion Biotechnologies shares have gained 40.35 percent over the past 52 weeks, while the S&P 500 index has surged 12.25 percent in the same period. Lion Biotechnologies' shares rose 4.23 percent to $12.58 in pre-market trading.
Posted In: InitiationAnalyst RatingsChardan Capital
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...